EP0610320A1 - Purified chitin deacetylase - Google Patents

Purified chitin deacetylase

Info

Publication number
EP0610320A1
EP0610320A1 EP92922352A EP92922352A EP0610320A1 EP 0610320 A1 EP0610320 A1 EP 0610320A1 EP 92922352 A EP92922352 A EP 92922352A EP 92922352 A EP92922352 A EP 92922352A EP 0610320 A1 EP0610320 A1 EP 0610320A1
Authority
EP
European Patent Office
Prior art keywords
chitin deacetylase
chitin
deacetylase
liquid phase
immunoadsorbent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92922352A
Other languages
German (de)
French (fr)
Other versions
EP0610320B1 (en
Inventor
Vassilis Bouriotis
Dimitri Kafetzopoulos
John J. Vournakis
Aggeliki Martinou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOTECHNOLOGY TRADING COMPANY Inc
Original Assignee
BIOTECHNOLOGY TRADING COMPANY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOTECHNOLOGY TRADING COMPANY Inc filed Critical BIOTECHNOLOGY TRADING COMPANY Inc
Publication of EP0610320A1 publication Critical patent/EP0610320A1/en
Application granted granted Critical
Publication of EP0610320B1 publication Critical patent/EP0610320B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/911Microorganisms using fungi
    • Y10S435/931Mucor

Definitions

  • chitin is the world's most abundant, easily obtained, and renewable biological material. It is a natural product synthesized by a wide variety of organisms. Several billion tons of the material are produced annually.
  • Chitin is a carbohydrate polymer, the N-acetylated polymer of S(l ⁇ 4) linked N-acetylglucosamine, or poly-N- acetyl glucosamine.
  • chitin is a cell wall constituent replacing cellulose or sometimes occurring together with cellulose.
  • chitin is usually organized as a cuticle at one surface of the epithelial tissue.
  • structurally similar to cellulose chitin has distinctly different chemical properties. It is an extremely insoluble material, with limited industrial applicability.
  • Chitosan is positively charged, thus, it can be used as a protein precipitant and a metal chelating agent. It can be formulated as a solution, gel, membrane, film or fiber. Such formulations are useful, for example, in the areas of precious metal recovery, crop protection, chromatography and enzyme immobilization.
  • Chitosan is a biologically benign, non-immunogenic, material making it ideal for use in the agricultural, food, drug and cosmetic industries. It can form complexes with other natural polymers, such as collagen and keratin, to form materials with unique biomedical properties.
  • Chitin comprises about 20-50% of the dry weight of crustacean cuticles, the balance being primarily calcium carbonate, calcium phosphate and other proteins. Chitin is first isolated by treating ground crustacean shells with dilute acid and alkali to remove proteins and minerals. The raw chitin is then deacetylated by exposure to concentrated alkali at high temperature to generate chitosan.
  • the subject invention relates to an essentially pure preparation of chitin deacetylase and to methods for isolating same from a cellular extract.
  • the invention relates to immunoglobulin specifically reactive with chitin deacetylase.
  • the invention relates to the use of the purified enzyme in a method for converting chitin to chitosan, and to the product produced by the method.
  • the purified enzyme is useful, for example, in the conversion of chitin to chitosan.
  • the enzymatic conversion of chitin to chitosan provides an attractive alternative to presently employed chemical methods which suffer from a variety of technical drawbacks, some of which have been discussed above. Brief Description of the Drawings
  • Figure 1 is a diagram representing the elution profile from a Phenyl Sepharose® CL-4B column.
  • Figure 2 is a diagram representing the elution profile from a Q Sepharose® Fast Flow column.
  • Figure 3 is a diagram representing the elution profile from an S Sepharose® Fast Flow column.
  • Figure 4 is a diagram which represents the temperature dependence of chitin deacetylase activity.
  • Figure 5 is a diagram which represents the pH dependence of chitin deacetylase activity.
  • the present invention was made possible by the discovery of a method for purifying chitin deacetylase from a cellular extract of an organism which produces chitin deacetylase.
  • the enzyme chitin deacetylase is produced by a variety of genera including, for example, Micor. Phycomyces , Absidia. and Choanephora. Other potentially useful genera include Zycrorhynchus , Actinomucor. Circinella, Rhizopus, Colletotrichum and Rhizomucor.
  • a preferred source for chitin deacetylase is the cell wall of fungal mycelia. Such mycelia are produced in great quantities as a byproduct of the fermentation industry.
  • the growth of Mucor rouxii in standard fermentors has been described in the literature.
  • the use of a fungus such as Mucor rouxii offers a number of advantages.
  • the organism can be grown using inexpensive nutrients. It can be grown to a high cell density (grams of cell dry weight per liter of culture medium) in a large scale fermentation system. The culture time required to achieve high cell density is as low as 12 hours/batch. Initially, cellular extract is prepared from an organism which produces chitin deacetylase.
  • the organism is a fungus (e.g., Mucor rouxii) mycelial cells are disrupted in the presence of an extraction buffer.
  • the extraction buffer may contain protease inhibitors, other degradative enzyme inhibitors and stabilizers to maintain enzyme activity and facilitate its extraction.
  • Non-soluble material is removed from the liquid phase of the extraction mixture, for example, by filtration or centrifugation.
  • the cellular extract is subjected to a thermal cycling step which results in the precipitation of undesirable protein (i.e., protein other than chitin deacetylase).
  • undesirable protein i.e., protein other than chitin deacetylase
  • the extract can be incubated at about 50°C for a period of about 15-30 minutes.
  • the precipitated protein is subsequently removed, for example, by filtration or centrifugation.
  • solubility properties of proteins in solutions having high salt concentrations vary over a wide range. This difference in solubility can be exploited to achieve separation of protein in a solution by precipitation at high ionic strength.
  • Many salts can be used for this purpose, but ammonium sulfate is preferred by virtue of the fact that it does not appreciably alter pH, it is highly soluble, and it does not destabilize proteins.
  • an ammonium sulfate concentration of about 2.1 M effectively precipitates a wide variety of proteins from the liquid phase described above, without precipitating the chitin deacetylase. Proteins which precipitate in an ammonium sulfate concentration of about 2.1 M are removed from the solution by standard techniques (e.g., filtration or centrifugation).
  • hydrophobic interaction chromatography is widely employed for the purification of macromolecules on the basis of their varying strength of hydrophobic interaction with hydrophobic groups attached to an uncharged gel matrix. This technique is usually performed in the presence of moderately high concentrations of anti-chaotropic salts (salt promoted adsorption chromatography) .
  • anti-chaotropic salts salt promoted adsorption chromatography
  • An example of a hydrophobic column resin is Phenyl Sepharose® 6 Fast Flow. Material bound by a hydrophobic adsorbent is removed from the column by passing, for example, water over the column.
  • an ion exchanger is a solid support that has chemically bound charged groups to which ions are electrostatically bound. A negatively charged group will exchange positive ions and is a cation exchanger. A positively charged group will exchange negative ions and is an anion exchanger.
  • Ion exchangers can be characterized as strong or weak ion exchangers. Strong ion exchangers function over a wide pH range and thus are useful for isolating a weakly ionized substance that requires very low or high pH for ionization.
  • the pH of the material which is recovered from the hydrophobic column is adjusted to about 8 and passed over a strong anion exchange column (e.g., Q Sepharose® Fast Flow). Fractions are collected and assayed for chitin deacetylase activity as described in the Exemplification section below. Fractions possessing chitin deacetylase activity are pooled and the pH of the pooled fractions is adjusted to about 3.5. The solution is then passed over a column which contains a strong cation exchange resin (e.g., S Sepharose® Fast Flow) and the flow through is collected. When analyzed by polyacrylamide gel electrophoresis, the flow through fraction contains an electrophoretically homogenous protein species.
  • the term essentially pure, as used herein, refers to a chitin deacetylase preparation which resolves substantially as a single band when analyzed by gel electrophoresis.
  • Applicants have employed purified immunoglobulin specifically reactive with chitin deacetylase.
  • Immunoglobulin having the desired properties can be produced by immunizing an animal with essentially pure chitin deacetylase.
  • Immunoglobulin having the desired properties can be attached to a solid support to form an immunoadsorbent.
  • the immunoadsorbent can then be used to purify the enzyme from a crude extract by conventional methods.
  • Chitin deacetylase prepared as described herein, can be used in a method for converting chitin to chitosan. Reaction parameters affecting enzyme activity are discussed in the Examples.
  • Mucor rouxii was obtained from the American Type Culture Collection (ATCC 24905) .
  • the fungus was grown in minimal medium as described by Bartnicki-Garcia and Nickerson fBacteriol. 84; 841-858 (1962)) in 16 liters batches.
  • Media was inoculated with 2 x 10* spores per liter and was stirred and aerated with sterile air for 24 hours at 28°C.
  • Mycelia were harvested at mid-log phase by filtration. Cultures yielded approximately 20 gr of mycelia (wet weight) per liter.
  • the crude extract was then incubated in a waterbath set at 50°C for 30 minutes and the precipitated material was removed by centrifugation at 8000g for 30 minutes at 4°C.
  • the supernatant from the 50° incubation was made 2.1 M in ammonium sulfate and the precipitated proteins were removed by centrifugation at lOOOOg for 45 minutes.
  • the supernatant (850ml) was then passed over a column (44 x 230mm) of Phenyl Sepharose® CL-4B equilibrated with 20mM Tris HCl (pH 7.5) containing 2.1 M ammonium sulfate.
  • Chitin deacetylase activity was estimated using as substrate partially O-hydroxyethylated chitin (glycol chitin) radiolabeled in N-acetyl groups.
  • the substrate preparation as well as the assay conditions were as described by Araki and Ito (Eur. J. Bioche . 55:71-78 (1975)) with the following modifications.
  • the assay mixture contained 0.1 mg/ml BSA buffered by 25 mM sodium glutamate at pH 4.5 (50°C) . Incubation time was 30 minutes at 50°C.
  • the sample of partially purified chitin deacetylase from the previous step was dialyzed against 20 mM Tris HC1 (pH 8) , and then passed over a column of Q Sepharose® Fast Flow (26 x 340 mm) equilibrated with the same buffer. After the column was washed, a linear gradient of NaCl (2000 ml, 0-0.75 M) buffered with 20 mM Tris HCl (pH 8), was established. Flow rate was 300 ml/h and fractions of 11.5 ml were collected. The elution profile is shown in Figure 2. Chitin deacetylase activity was detected in fractions 105-150 corresponding to -0.13 M NaCl. These fractions were pooled for further processing.
  • the pooled fractions were dialyzed against 25 mM sodium formate buffer, (pH 3.5), and the sample was loaded on an S Sepharose® Fast Flow column (26 x 280 mm) equilibrated with the same buffer.
  • the column was eluted at a flow rate of 250 ml/h with a linear gradient of NaCl (2000 ml, 0-1.2 M) in the buffer mentioned above. Fractions of 12 ml were collected. The elution profile is shown in Figure 3. The majority of chitin deacetylase activity was not retained by the column and was detected in the flow through fractions in an electrophoretically homogenous form.
  • the results of the purification scheme are summarized in Table 1.
  • the enzyme purified by this procedure was judged to be electrophoretically homogeneous, as tested by both native and SDS-PAGE. On a gradient (5-20%) SDS polyacryla ide gel the enzyme band migrated at a distance corresponding to molecular weight of -75 kDa.
  • purified chitin deacetylase was subjected to gel filtration on Sephacryl® S-200 HR it was eluted as a single peak with an apparent size of ⁇ 80 kDa indicating that the native enzyme exists as a monomer.
  • chitin deacetylase is a glycoprotein. After electrophoresis, the enzyme band gave a positive stain with periodate-Schiff's reagent on polyacrylamide gels. The enzyme was retained by a column of concanavalin A-Sepharose® 4B and recovered as a single peak by elution with a gradient of ⁇ -methyl mannoside at a position corresponding to approximately 25 mM. As shown in Table 2, direct carbohydrate analysis of the enzyme revealed that the protein contains 6 residues of fucose, 85 residues of mannose and 22 residues of N-acetylglucosamine per molecule contributing approximately 30% to its molecular weight. Sialic acid and other sugars were not found in significant amounts.
  • Monosaccharide analysis was carried out by gas-liquid chromatography and gas-liquid chromatography-mass spectrometry.
  • the sample was hydrolyzed in 4M tri- fluoroacetic acid at 100°C for 4 hours.
  • the molar ratio of carbohydrates per molecule was estimated by direct carbo ⁇ hydrate and amino acid composition analysis.
  • RNA encoding the enzyme was translated in vitro followed by immunoprecipitation.
  • mRNA was extracted from mycelia (15 g wet weight) harvested at the early log phase by grinding in liquid nitrogen. mRNA was purified by the guanidinium thiocyanate method of Chirwin et al. (Biochem. 18:5294-5299 (1979)) followed by pelleting in cesium chloride by ultracentrifugation.
  • Poly (A) + RNA (- 120 ⁇ g) was isolated by 3 passes through an oligo(dT)-cellulose column as described by Aviv and Leder (Proc.
  • Polyclonal antisera was prepared by emulsifying pure chitin deacetylase (500 ⁇ g, 1 mg/ml in PBS) with an equal volume of Freund's complete adjuvant. The mixture was injected intradermally into a rabbit after preim une serum was obtained. The animal was reimmunized and bled after four and six weeks with 200 ⁇ g of enzyme in Freund's incomplete adjuvant, also injected intradermally. Antisera obtained were monitored for the presence of anti-chitin deacetylase antibodies by ELISA and by enzyme activity inhibition assays.
  • Immunoprecipitates were boiled for 5 min in SDS-PAGE loading buffer and analyzed by gel electrophoresis. The gel was fixed for 30 min in 10% acetic acid, 30% methanol, incubated for 30 min in EN 3 HANCE® (New England Nuclear) and then dried and exposed. In vitro translation products were analyzed on a 12% SDS polyacrylamide gel followed by autoradiography. The material immunoprecipitated by the specific antiserum showed one band corresponding to molecular weight of -49000 kDa that represents the size of the polypeptide chain prior to any post-translational modification.
  • the temperature optimum of the enzyme activity was estimated to be -50°C using labeled glycol chitin, as substrate as described above.
  • the temperature dependence of the chitin deacetylase activity is shown graphically in Figure 1.
  • the pH optimum was estimated to be -4.5, tested with a combination of overlapping buffers, as shown graphically in Figure 2.
  • Chitin deacetylase (5mU) when incubated with 1 mg of partially chemically deacetylated chitosan (81%) for one hour, released 0.22 ⁇ moles of acetic acid corresponding to an increment of -5.3% in deacetylation degree.
  • the enzyme was also active on macrocrystalline chitin (colloidal chitin) and carboxymethyl chitin (soluble derivative) .
  • the amino acid composition of chitin deacetylase is shown in Table 3. Basic amino acids accounted only for -8% of the total amino acids, a value -40% lower than the average.
  • Amino acid composition of purified chitin deacetylase was determined after 24 hour hydrolysis with 6M HCl at 100°C. The values are means of two different sample determinations. The number of residues per molecule of protein is based on the estimated molecular weight of 49000 Da from SDS-PAGE of the immunoprecipitated product from in vitro translation of mRNA. Table 3
  • An adult male white New Zealand rabbit was immunized with 500 ⁇ g (1 mg/ml in PBS) of purified chitin deacetylase, prepared as described in Example 1, from the fungus Mucor rouxii.
  • the enzyme was emulsified with an equal volume of Freund's complete adjuvant in a total volume of 1 ml, and was administered to the animal intradermally.
  • a further three booster doses of 150 ⁇ g of chitin deacetylase emulsified in Freund's incomplete adjuvant were administered at 4-week intervals. Test bleeds from the marginal ear vein were used to monitor serum antibody titer by ELISA. Control serum was taken prior to immunization.
  • the specificity of the antiserum produced was analyzed in a chitin deacetylase inhibition assay.
  • Chitin deacetylase activity was assayed by measuring the radioactivity of [ 3 H]-acetic acid liberated from a water- soluble chitin derivative, glycol [acetyl- 3 H] chitin.
  • the reaction mixture contained 48 ⁇ g of glycol [acetyl- 3 H] chitin, ImM magnesium chloride, O.lmg/ml BSA and was buffered by 25mM sodium glutamate (pH 4.5) in a total volume of 50 ⁇ l.
  • Antibody titer was monitored using a non-competitive ELISA.
  • Chitin deacetylase was immobilized onto microtiter plates (Maxi Sorp, Nunc, Denmark) at 2 ⁇ g/ml of "coating" buffer (pH 9.6), containing 0.05 M sodium carbonate and sodium bicarbonate by incubation overnight at 4°C.
  • Wells were washed out with 0.05% aqueous solution of Tween 80 followed by two washes with distilled water. After that 200 ⁇ l of blocking agent per well was incubated for 1 hour at room temperature.
  • the blocking agent was 1 g of bovine serum albumin dissolved in 100 ml of 0.010 M PBS (pH 7.4). Wells were washed out as before.
  • An anti-rabbit IgG conjugated to horseradish peroxidase was used to indirectly detect specific IgG bound to immobilized chitin deacetylase.
  • the conjugate was diluted 10,000-fold in 0.010 M PBS (pH 7.4) and incubated at 100 ⁇ l per well for one hour at room temperature. Wells were washed out with H 2 0/Tween 80 solution as before, followed by two washes with distilled water. Wells were aspirated and incubated with 100 ⁇ l of substrate/chromogen solution made up just prior to use as follows: The reaction was stopped after 15 minutes by addition of 50 ⁇ l of 4M sulfuric acid per well. Absorbance was read at 450 nm using an ELISA reader. The enzyme activity of a defined amount of purified chitin deacetylase was measured after incubation with various amounts of antiserum. These experiments confirmed that a component of the antiserum was specifically reactive with chitin deacetylase.
  • IgG was affinity-purified from rabbit serum using chitin deacetylase immobilized to cyanogen bromide-activated Sepharose 4B (Pharmacia Ltd.) according to manufacturer's instructions.
  • a solution containing ten milligrams of purified chitin deacetylase was dialyzed against 2 It of "coupling buffer" (pH 8.3), containing 0.1 M sodium bicarbonate and 0.5 M sodium chloride.
  • Preswollen cyanogen bromide-activated Sepharose 4B equilibrated with coupling buffer was mixed with chitin deacetylase (1.4 mg protein/ml of gel) overnight at 4°C by end over end rotation. This mixture was transferred to a scintered glass funnel and sucked dry under vacuum.
  • the fluid was recovered and assayed for protein to assess coupling efficiency.
  • the gel was washed thoroughly with coupling buffer and mixed as before for 2 hours with Tris-HCl buffer (0.1 M, pH 8.0) at room temperature.
  • Tris-HCl buffer 0.1 M, pH 8.0
  • the gel was sucked dry and washed with coupling buffer. Protein noncovalently adsorbed to the gel was removed by washing the gel with alternating buffers of low (0.1 M sodium acetate, 0.5 M sodium chloride, pH 4.0) and high pH (0.1 M Tris, 0.5 M sodium chloride, pH 8.3).
  • the chitin deacetylase-linked Sepharose 4B was transferred to a mini-column and washed with 0.025 M Tris-HCl (pH 7.4) which contained 0.02% sodium azide during storage at 4°C.
  • the concentration of antibody in solution can be estimated by measuring A 2g0 using an average extinction coefficient for antibodies of 1.4 for 1 mg ml' 1 protein using a 1 cm path length cell.
  • Rabbit antiserum against chitin deacetylase obtained from various bleedings was separately precipitated by 40% saturation of ammonium sulfate.
  • the immunoglobulin containing precipitate was dissolved and dialyzed extensively against 0.025 M Tris (pH 7.4), 0.2 M sodium chloride and subsequently passed through the chitin deacetylase-linked Sepharose 4B column (including protease inhibitors) .
  • the gel was washed with ten column volumes of 0.025 M Tris, 0.1 M sodium chloride (pH 7.4), until collected fractions gave negligible readings at 280 nm.
  • Non-specifically bound proteins were eluted with 0.025 M Tris, 1M sodium chloride, pH 7.4.
  • a batch of IgG was eluted with two column volumes of 0.1 M glycine-hydrochloric acid buffer (pH 2.8) .
  • a further batch of higher affinity IgG was eluted with two column volumes of 0.2 M glycine-hydrochloric acid, pH 2.2.
  • affinity refers to the functional affinity (avidity) as polyclonal antibodies were used. All fractions were immediately adjusted to pH 7.0 with 1M Tris - HCl (pH 9.0). The two populations of IgG fractions were pooled separately and concentrated by ultrafiltration prior to dialysis against 0.025 M Tris (pH 7.4).
  • the purified specific IgG shows the characteristic rabbit IgG pattern in SDS-PAGE. Pure specific IgG is stored at -20°C at a concentration > 1 mg/ml in 0.010 M Tris, 0.1 M sodium chloride (pH 7.4).
  • the coupling of chitin deacetylase to cyanogen bromide- activated Sepharose 4B was 90% efficient, producing chitin deacetylase-linked Sepharose 4B at 1.4 mg of chitin deacetylase/ml of gel.
  • about 2.0 - 6.5 mg of pure specific IgG were isolated from every 10 ml of antiserum with the elution of pH 2.8 (2.0% to 5.0% of total protein after ammonium sulfate precipitation) .
  • Total isolated specific IgG represents 4.5% to 8.0% of total protein after ammonium sulfate precipitation.
  • the binding capacity of the chitin deacetylase-linked Sepharose 4B for anti-chitin deacetylase antibody was determined at 1.4 mg IgG/ml of gel.
  • Frozen mycelia (2 gr) prepared as described in Example 1, was thawed, minced and homogenized in 10 ml of 0.05 M Tris-HCl buffer (pH 7.4) containing 0.5 mM PMSF, 0.1 mM NEM and 150 mM NaCl, using an improvised glass-bead miller (2 gr glass beads per gram of wet mycelia) . All steps were performed at 4°C. This produced a homogenate which was centrifuged at 10,000 rpm for 30 minutes at 4°C. The supernatant (12.2 ml; 4.6 mg/ml; 56.0 mg) is referred to as the crude extract. The extract was then incubated in a waterbath set at 50°C for 15 minutes and rapidly cooled in ice. Precipitated protein was removed by centrifugation at 35,000 rpm for 45 minutes at 4°C.
  • Example 2 Five milligrams of the pure lower affinity rabbit IgG, described in Example 2, was dialyzed against the coupling buffer (pH 8.3) and mixed with 5 ml of swollen CNBr- activated Sepharose 4B to prepare an immunoadsorbent.
  • the IgG was coupled by the method described for chitin deacetylase coupling.
  • the coupling of IgG to activated Sepharose 4B was 85% efficient, producing IgG-linked Sepharose at 1 mg IgG/ml of gel. This immunoadsorbent was used for chitin deacetylase purification.
  • the supernatant described above (11.5 ml; 0.54 mg/ml; 6.2 mg) was loaded onto the immunoadsorbent (packed in a column of dimensions 2 x 1.6 cm; 5 ml) previously equilibrated in 25 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl (buffer A) .
  • the column was washed with buffer A until no absorption of 280 nm was evident in the effluents (non-specifically bound proteins were eluted with 25 mM Tris-HCl pH 7.4, IM NaCl).
  • chitin deacetylase was eluted using 0.2 M glycine-HCl buffer (pH 2.8) at a flow rate of 35 ml/h. Eluate was immediately adjusted to pH 7.0 with IM Tris-HCl pH 9.0, dialyzed against buffer A and concentrated by ultrafiltration (300 ⁇ l; 40 ⁇ g/ml; 12 ⁇ g; 180 mU) .
  • chitin deacetylase Purification of chitin deacetylase by immunoadsorption (table 4) produced a specific activity of 1500 m units/mg for the desorbed enzyme and a yield of about 30%. Assessment of chitin deacetylase purity by SDS-PAGE shows a single band. Purification of chitin deacetylase by conventional methods (table 1) produced a pure enzyme with a specific activity of 3.23 units/mg and a yield of 11.8%. The maximum binding capacity of the immunoadsorbent was determined at 42 ⁇ g of chitin deacetylase/ml of gel (4% of the antigen binding sites remain available for binding antigen after covalent immobilization to the matrix) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La désacetylase de chitine, l'enzyme qui catalyse l'hydrolyse de groupes acétamide de N-acétylglucosamine dans la chitine, a été purifiée de façon à se présenter sous une forme homogène à partir d'extraits mycéliens du champignon Mucor rouxii. En outre, une immunoglobuline réagissant spécifiquement avec la désacétylase de chitine a été produite et purifiée.Chitin deacetylase, the enzyme that catalyzes the hydrolysis of acetamide groups of N-acetylglucosamine in chitin, has been purified so as to be in a homogeneous form from mycelial extracts of the fungus Mucor rouxii. In addition, an immunoglobulin specifically reacting with chitin deacetylase was produced and purified.

Description

PURIFIED CHITIN DEACETYLASE
Background of the Invention
Next to cellulose, chitin is the world's most abundant, easily obtained, and renewable biological material. It is a natural product synthesized by a wide variety of organisms. Several billion tons of the material are produced annually.
Chitin is a carbohydrate polymer, the N-acetylated polymer of S(l→4) linked N-acetylglucosamine, or poly-N- acetyl glucosamine. In plants, chitin is a cell wall constituent replacing cellulose or sometimes occurring together with cellulose. In animals, chitin is usually organized as a cuticle at one surface of the epithelial tissue. Although structurally similar to cellulose, chitin has distinctly different chemical properties. It is an extremely insoluble material, with limited industrial applicability.
The deacetylated derivative of chitin, chitosan, is a much more tractable material with a broad and impressive array of practical applications. Chitosan is positively charged, thus, it can be used as a protein precipitant and a metal chelating agent. It can be formulated as a solution, gel, membrane, film or fiber. Such formulations are useful, for example, in the areas of precious metal recovery, crop protection, chromatography and enzyme immobilization. Chitosan is a biologically benign, non-immunogenic, material making it ideal for use in the agricultural, food, drug and cosmetic industries. It can form complexes with other natural polymers, such as collagen and keratin, to form materials with unique biomedical properties. For example, such materials can be used as wound healing accelerants, components of artificial skin and blood vessels, anticoagulants, and controlled drug release vehicles. At present the bulk of the chitosan produced worldwide is prepared from crustacean shell material. Chitin comprises about 20-50% of the dry weight of crustacean cuticles, the balance being primarily calcium carbonate, calcium phosphate and other proteins. Chitin is first isolated by treating ground crustacean shells with dilute acid and alkali to remove proteins and minerals. The raw chitin is then deacetylated by exposure to concentrated alkali at high temperature to generate chitosan. Although the chitosan produced in this manner has many useful features, it is impossible to effectively control the production process, which leads to the production of a material having a broad range of molecular weight and a heterogenous extent of deacetylation. Such a product is not of great value, since many of the potentially important applications, particularly in the biomedical area, require uniform material with very specific physical and chemical properties.
Summary of the Invention
The subject invention relates to an essentially pure preparation of chitin deacetylase and to methods for isolating same from a cellular extract. In addition, the invention relates to immunoglobulin specifically reactive with chitin deacetylase. In another aspect, the invention relates to the use of the purified enzyme in a method for converting chitin to chitosan, and to the product produced by the method.
The purified enzyme is useful, for example, in the conversion of chitin to chitosan. The enzymatic conversion of chitin to chitosan provides an attractive alternative to presently employed chemical methods which suffer from a variety of technical drawbacks, some of which have been discussed above. Brief Description of the Drawings
Figure 1 is a diagram representing the elution profile from a Phenyl Sepharose® CL-4B column.
Figure 2 is a diagram representing the elution profile from a Q Sepharose® Fast Flow column.
Figure 3 is a diagram representing the elution profile from an S Sepharose® Fast Flow column.
Figure 4 is a diagram which represents the temperature dependence of chitin deacetylase activity.
Figure 5 is a diagram which represents the pH dependence of chitin deacetylase activity.
Detailed Description of the Invention
The present invention was made possible by the discovery of a method for purifying chitin deacetylase from a cellular extract of an organism which produces chitin deacetylase. The enzyme chitin deacetylase is produced by a variety of genera including, for example, Micor. Phycomyces , Absidia. and Choanephora. Other potentially useful genera include Zycrorhynchus , Actinomucor. Circinella, Rhizopus, Colletotrichum and Rhizomucor.
A preferred source for chitin deacetylase is the cell wall of fungal mycelia. Such mycelia are produced in great quantities as a byproduct of the fermentation industry. The growth of Mucor rouxii in standard fermentors has been described in the literature. The use of a fungus such as Mucor rouxii offers a number of advantages. The organism can be grown using inexpensive nutrients. It can be grown to a high cell density (grams of cell dry weight per liter of culture medium) in a large scale fermentation system. The culture time required to achieve high cell density is as low as 12 hours/batch. Initially, cellular extract is prepared from an organism which produces chitin deacetylase. For example, if the organism is a fungus (e.g., Mucor rouxii) mycelial cells are disrupted in the presence of an extraction buffer. The extraction buffer may contain protease inhibitors, other degradative enzyme inhibitors and stabilizers to maintain enzyme activity and facilitate its extraction. Non-soluble material is removed from the liquid phase of the extraction mixture, for example, by filtration or centrifugation.
The cellular extract is subjected to a thermal cycling step which results in the precipitation of undesirable protein (i.e., protein other than chitin deacetylase). For example, as described in the Examples below, the extract can be incubated at about 50°C for a period of about 15-30 minutes. The precipitated protein is subsequently removed, for example, by filtration or centrifugation.
It is well known that the solubility properties of proteins in solutions having high salt concentrations vary over a wide range. This difference in solubility can be exploited to achieve separation of protein in a solution by precipitation at high ionic strength. Many salts can be used for this purpose, but ammonium sulfate is preferred by virtue of the fact that it does not appreciably alter pH, it is highly soluble, and it does not destabilize proteins.
Applicants' have determined that an ammonium sulfate concentration of about 2.1 M effectively precipitates a wide variety of proteins from the liquid phase described above, without precipitating the chitin deacetylase. Proteins which precipitate in an ammonium sulfate concentration of about 2.1 M are removed from the solution by standard techniques (e.g., filtration or centrifugation).
The liquid phase which is recovered following the ammonium sulfate precipitation is subjected to hydrophobic interaction chromatography. Hydrophobic interaction chromatography is widely employed for the purification of macromolecules on the basis of their varying strength of hydrophobic interaction with hydrophobic groups attached to an uncharged gel matrix. This technique is usually performed in the presence of moderately high concentrations of anti-chaotropic salts (salt promoted adsorption chromatography) . Several factors influence the chro atographic behavior of proteins and peptides on hydrophobic adsorbents. These factors include ligand structure, ligand density, sample characteristics, flow rate, salting-out effect, ionic strength, temperature and pH. An example of a hydrophobic column resin is Phenyl Sepharose® 6 Fast Flow. Material bound by a hydrophobic adsorbent is removed from the column by passing, for example, water over the column.
Following hydrophobic interaction chromatography, the solution containing the chitin deacetylase is further purified by ion-exchange chromatography. An ion exchanger is a solid support that has chemically bound charged groups to which ions are electrostatically bound. A negatively charged group will exchange positive ions and is a cation exchanger. A positively charged group will exchange negative ions and is an anion exchanger.
Ion exchangers can be characterized as strong or weak ion exchangers. Strong ion exchangers function over a wide pH range and thus are useful for isolating a weakly ionized substance that requires very low or high pH for ionization.
The pH of the material which is recovered from the hydrophobic column is adjusted to about 8 and passed over a strong anion exchange column (e.g., Q Sepharose® Fast Flow). Fractions are collected and assayed for chitin deacetylase activity as described in the Exemplification section below. Fractions possessing chitin deacetylase activity are pooled and the pH of the pooled fractions is adjusted to about 3.5. The solution is then passed over a column which contains a strong cation exchange resin (e.g., S Sepharose® Fast Flow) and the flow through is collected. When analyzed by polyacrylamide gel electrophoresis, the flow through fraction contains an electrophoretically homogenous protein species. The term essentially pure, as used herein, refers to a chitin deacetylase preparation which resolves substantially as a single band when analyzed by gel electrophoresis.
In a second method of purification, Applicants have employed purified immunoglobulin specifically reactive with chitin deacetylase. Immunoglobulin having the desired properties can be produced by immunizing an animal with essentially pure chitin deacetylase. Immunoglobulin having the desired properties can be attached to a solid support to form an immunoadsorbent. The immunoadsorbent can then be used to purify the enzyme from a crude extract by conventional methods.
Chitin deacetylase, prepared as described herein, can be used in a method for converting chitin to chitosan. Reaction parameters affecting enzyme activity are discussed in the Examples.
Examples
Example 1: First Method for Purifying Chitin Deacetylase
Fermentation of Mucor rouxii
Mucor rouxii was obtained from the American Type Culture Collection (ATCC 24905) . The fungus was grown in minimal medium as described by Bartnicki-Garcia and Nickerson fBacteriol. 84; 841-858 (1962)) in 16 liters batches. Media was inoculated with 2 x 10* spores per liter and was stirred and aerated with sterile air for 24 hours at 28°C. Mycelia were harvested at mid-log phase by filtration. Cultures yielded approximately 20 gr of mycelia (wet weight) per liter.
Extraction and Purification of Chitin Deacetylase
400 g of mycelia were extracted by blending with 600 g of glass beads and 700ml of extraction buffer containing 50mM Tris HC1 (pH 7.8), lOOmM NaCl and 0.2 mM PMSF for one hour over ice. After the extraction was completed the glass beads were settled and removed and the extract was centrifuged for 30 minutes at 8000 g at 4°C. The supernatant (750ml) is referred to as the crude extract.
The crude extract was then incubated in a waterbath set at 50°C for 30 minutes and the precipitated material was removed by centrifugation at 8000g for 30 minutes at 4°C. The supernatant from the 50° incubation was made 2.1 M in ammonium sulfate and the precipitated proteins were removed by centrifugation at lOOOOg for 45 minutes. The supernatant (850ml) was then passed over a column (44 x 230mm) of Phenyl Sepharose® CL-4B equilibrated with 20mM Tris HCl (pH 7.5) containing 2.1 M ammonium sulfate. After the column was washed with the buffer mentioned above, the retained proteins were eluted with a 2100ml linear gradient of decreasing ammonium sulfate concentration. Flow rate was 250ml/h and fractions of 14 ml were collected. The elution profile is shown in Figure 1. Chitin deacetylase activity was detected in fractions 195-295 which were pooled for further purification. The protein content was followed by a UV monitor at 280 nm.
Chitin deacetylase activity was estimated using as substrate partially O-hydroxyethylated chitin (glycol chitin) radiolabeled in N-acetyl groups. The substrate preparation as well as the assay conditions were as described by Araki and Ito (Eur. J. Bioche . 55:71-78 (1975)) with the following modifications. The assay mixture contained 0.1 mg/ml BSA buffered by 25 mM sodium glutamate at pH 4.5 (50°C) . Incubation time was 30 minutes at 50°C.
The sample of partially purified chitin deacetylase from the previous step was dialyzed against 20 mM Tris HC1 (pH 8) , and then passed over a column of Q Sepharose® Fast Flow (26 x 340 mm) equilibrated with the same buffer. After the column was washed, a linear gradient of NaCl (2000 ml, 0-0.75 M) buffered with 20 mM Tris HCl (pH 8), was established. Flow rate was 300 ml/h and fractions of 11.5 ml were collected. The elution profile is shown in Figure 2. Chitin deacetylase activity was detected in fractions 105-150 corresponding to -0.13 M NaCl. These fractions were pooled for further processing.
The pooled fractions were dialyzed against 25 mM sodium formate buffer, (pH 3.5), and the sample was loaded on an S Sepharose® Fast Flow column (26 x 280 mm) equilibrated with the same buffer. The column was eluted at a flow rate of 250 ml/h with a linear gradient of NaCl (2000 ml, 0-1.2 M) in the buffer mentioned above. Fractions of 12 ml were collected. The elution profile is shown in Figure 3. The majority of chitin deacetylase activity was not retained by the column and was detected in the flow through fractions in an electrophoretically homogenous form.
Characterization of Purified Enzyme a) molecular weight
The results of the purification scheme are summarized in Table 1. The enzyme purified by this procedure was judged to be electrophoretically homogeneous, as tested by both native and SDS-PAGE. On a gradient (5-20%) SDS polyacryla ide gel the enzyme band migrated at a distance corresponding to molecular weight of -75 kDa. When purified chitin deacetylase was subjected to gel filtration on Sephacryl® S-200 HR it was eluted as a single peak with an apparent size of ~80 kDa indicating that the native enzyme exists as a monomer.
Table 1
Purification of chitin deacetylase
b) carbohydrate content
Several pieces of evidence suggest that chitin deacetylase is a glycoprotein. After electrophoresis, the enzyme band gave a positive stain with periodate-Schiff's reagent on polyacrylamide gels. The enzyme was retained by a column of concanavalin A-Sepharose® 4B and recovered as a single peak by elution with a gradient of α-methyl mannoside at a position corresponding to approximately 25 mM. As shown in Table 2, direct carbohydrate analysis of the enzyme revealed that the protein contains 6 residues of fucose, 85 residues of mannose and 22 residues of N-acetylglucosamine per molecule contributing approximately 30% to its molecular weight. Sialic acid and other sugars were not found in significant amounts.
Monosaccharide analysis was carried out by gas-liquid chromatography and gas-liquid chromatography-mass spectrometry. The sample was hydrolyzed in 4M tri- fluoroacetic acid at 100°C for 4 hours. The molar ratio of carbohydrates per molecule was estimated by direct carbo¬ hydrate and amino acid composition analysis.
Table 2
c) immunoprecipitation of in vitro translation product In order to determine the size of the chitin deacetylase polypeptide. chain in an alternative manner, mRNA encoding the enzyme was translated in vitro followed by immunoprecipitation. mRNA was extracted from mycelia (15 g wet weight) harvested at the early log phase by grinding in liquid nitrogen. mRNA was purified by the guanidinium thiocyanate method of Chirwin et al. (Biochem. 18:5294-5299 (1979)) followed by pelleting in cesium chloride by ultracentrifugation. Poly (A)+ RNA (- 120 μg) was isolated by 3 passes through an oligo(dT)-cellulose column as described by Aviv and Leder (Proc. Natl. Acad. Sci. , USA 69:1408-1412 (1972)). In vitro translation of total mRNA was performed using nuclease treated rabbit reticulocyte lysate according to the manufacturer's instructions. In vitro translation products were labeled with 35S-methionine.
Polyclonal antisera was prepared by emulsifying pure chitin deacetylase (500 μg, 1 mg/ml in PBS) with an equal volume of Freund's complete adjuvant. The mixture was injected intradermally into a rabbit after preim une serum was obtained. The animal was reimmunized and bled after four and six weeks with 200 μg of enzyme in Freund's incomplete adjuvant, also injected intradermally. Antisera obtained were monitored for the presence of anti-chitin deacetylase antibodies by ELISA and by enzyme activity inhibition assays.
After the in vitro translation reaction was completed, lOμl of preimmune serum were added and the reaction was incubated for 30 minutes at room temperature. Antigen- antibody complexes were removed by centrifugation after adsorption to lOμl of Protein A-Sepharose® added to the reaction. Specific polyclonal antiserum (lOμl) was then added to the supernatant which was subsequently incubated as described above. The new antigen-antibody complexes were collected using protein A-Sepharose® by centrifugation and then washed three times with 20 volumes of 25mM Tris HCl (pH 7.5), 150mM NaCl by resuspension and pelleting. Immunoprecipitates were boiled for 5 min in SDS-PAGE loading buffer and analyzed by gel electrophoresis. The gel was fixed for 30 min in 10% acetic acid, 30% methanol, incubated for 30 min in EN3HANCE® (New England Nuclear) and then dried and exposed. In vitro translation products were analyzed on a 12% SDS polyacrylamide gel followed by autoradiography. The material immunoprecipitated by the specific antiserum showed one band corresponding to molecular weight of -49000 kDa that represents the size of the polypeptide chain prior to any post-translational modification.
d) enzyme activity characterization
The temperature optimum of the enzyme activity was estimated to be -50°C using labeled glycol chitin, as substrate as described above. The temperature dependence of the chitin deacetylase activity is shown graphically in Figure 1. The pH optimum was estimated to be -4.5, tested with a combination of overlapping buffers, as shown graphically in Figure 2. Chitin deacetylase (5mU) when incubated with 1 mg of partially chemically deacetylated chitosan (81%) for one hour, released 0.22 μmoles of acetic acid corresponding to an increment of -5.3% in deacetylation degree. The enzyme was also active on macrocrystalline chitin (colloidal chitin) and carboxymethyl chitin (soluble derivative) .
e) amino acid composition
The amino acid composition of chitin deacetylase is shown in Table 3. Basic amino acids accounted only for -8% of the total amino acids, a value -40% lower than the average.
Amino acid composition of purified chitin deacetylase was determined after 24 hour hydrolysis with 6M HCl at 100°C. The values are means of two different sample determinations. The number of residues per molecule of protein is based on the estimated molecular weight of 49000 Da from SDS-PAGE of the immunoprecipitated product from in vitro translation of mRNA. Table 3
Example 2: Production and Purification of Antibodies Reactive with Chitin Deacetylase
An adult male white New Zealand rabbit was immunized with 500 μg (1 mg/ml in PBS) of purified chitin deacetylase, prepared as described in Example 1, from the fungus Mucor rouxii. The enzyme was emulsified with an equal volume of Freund's complete adjuvant in a total volume of 1 ml, and was administered to the animal intradermally. A further three booster doses of 150 μg of chitin deacetylase emulsified in Freund's incomplete adjuvant were administered at 4-week intervals. Test bleeds from the marginal ear vein were used to monitor serum antibody titer by ELISA. Control serum was taken prior to immunization.
The specificity of the antiserum produced was analyzed in a chitin deacetylase inhibition assay. Chitin deacetylase activity was assayed by measuring the radioactivity of [3H]-acetic acid liberated from a water- soluble chitin derivative, glycol [acetyl-3H] chitin. The reaction mixture contained 48 μg of glycol [acetyl-3H] chitin, ImM magnesium chloride, O.lmg/ml BSA and was buffered by 25mM sodium glutamate (pH 4.5) in a total volume of 50 μl. After incubation at 50°C for 15 min, the reaction was terminated by the addition of 16 μl of HCl, 4 μl of acetic acid and 80 μl of water. Ethyl acetate (0.5 ml) was added to the mixture, and the solution was vigorously mixed with a vortex mixer for 5 minutes and centrifuged at 14000 rp . 4.5 ml of toluene-based liquid scintillation cocktail was added to 200 μl of the organic phase solution and swirled. The solution was transferred to a vial and measured for radioactivity in a liquid scintillation counter. One unit of enzyme releases 1.0 μmol of the acetic acid from glycol chitin per minute under the conditions described above. Specific activity was defined as the units of enzyme per milligram of protein. Protein was assayed by the so-called Lowry method using bovine serum albumin as a standard.
Antibody titer was monitored using a non-competitive ELISA. Chitin deacetylase was immobilized onto microtiter plates (Maxi Sorp, Nunc, Denmark) at 2μg/ml of "coating" buffer (pH 9.6), containing 0.05 M sodium carbonate and sodium bicarbonate by incubation overnight at 4°C. Wells were washed out with 0.05% aqueous solution of Tween 80 followed by two washes with distilled water. After that 200 μl of blocking agent per well was incubated for 1 hour at room temperature. The blocking agent was 1 g of bovine serum albumin dissolved in 100 ml of 0.010 M PBS (pH 7.4). Wells were washed out as before. An anti-rabbit IgG conjugated to horseradish peroxidase was used to indirectly detect specific IgG bound to immobilized chitin deacetylase. The conjugate was diluted 10,000-fold in 0.010 M PBS (pH 7.4) and incubated at 100 μl per well for one hour at room temperature. Wells were washed out with H20/Tween 80 solution as before, followed by two washes with distilled water. Wells were aspirated and incubated with 100 μl of substrate/chromogen solution made up just prior to use as follows: The reaction was stopped after 15 minutes by addition of 50 μl of 4M sulfuric acid per well. Absorbance was read at 450 nm using an ELISA reader. The enzyme activity of a defined amount of purified chitin deacetylase was measured after incubation with various amounts of antiserum. These experiments confirmed that a component of the antiserum was specifically reactive with chitin deacetylase.
IgG was affinity-purified from rabbit serum using chitin deacetylase immobilized to cyanogen bromide-activated Sepharose 4B (Pharmacia Ltd.) according to manufacturer's instructions. A solution containing ten milligrams of purified chitin deacetylase was dialyzed against 2 It of "coupling buffer" (pH 8.3), containing 0.1 M sodium bicarbonate and 0.5 M sodium chloride. Preswollen cyanogen bromide-activated Sepharose 4B equilibrated with coupling buffer was mixed with chitin deacetylase (1.4 mg protein/ml of gel) overnight at 4°C by end over end rotation. This mixture was transferred to a scintered glass funnel and sucked dry under vacuum. The fluid was recovered and assayed for protein to assess coupling efficiency. The gel was washed thoroughly with coupling buffer and mixed as before for 2 hours with Tris-HCl buffer (0.1 M, pH 8.0) at room temperature. The gel was sucked dry and washed with coupling buffer. Protein noncovalently adsorbed to the gel was removed by washing the gel with alternating buffers of low (0.1 M sodium acetate, 0.5 M sodium chloride, pH 4.0) and high pH (0.1 M Tris, 0.5 M sodium chloride, pH 8.3). The chitin deacetylase-linked Sepharose 4B was transferred to a mini-column and washed with 0.025 M Tris-HCl (pH 7.4) which contained 0.02% sodium azide during storage at 4°C. The concentration of antibody in solution can be estimated by measuring A2g0 using an average extinction coefficient for antibodies of 1.4 for 1 mg ml'1 protein using a 1 cm path length cell.
Rabbit antiserum against chitin deacetylase obtained from various bleedings was separately precipitated by 40% saturation of ammonium sulfate. The immunoglobulin containing precipitate was dissolved and dialyzed extensively against 0.025 M Tris (pH 7.4), 0.2 M sodium chloride and subsequently passed through the chitin deacetylase-linked Sepharose 4B column (including protease inhibitors) . The gel was washed with ten column volumes of 0.025 M Tris, 0.1 M sodium chloride (pH 7.4), until collected fractions gave negligible readings at 280 nm. Non-specifically bound proteins were eluted with 0.025 M Tris, 1M sodium chloride, pH 7.4. A batch of IgG was eluted with two column volumes of 0.1 M glycine-hydrochloric acid buffer (pH 2.8) . A further batch of higher affinity IgG was eluted with two column volumes of 0.2 M glycine-hydrochloric acid, pH 2.2. The term affinity, as used herein, refers to the functional affinity (avidity) as polyclonal antibodies were used. All fractions were immediately adjusted to pH 7.0 with 1M Tris - HCl (pH 9.0). The two populations of IgG fractions were pooled separately and concentrated by ultrafiltration prior to dialysis against 0.025 M Tris (pH 7.4). The purified specific IgG shows the characteristic rabbit IgG pattern in SDS-PAGE. Pure specific IgG is stored at -20°C at a concentration > 1 mg/ml in 0.010 M Tris, 0.1 M sodium chloride (pH 7.4).
The coupling of chitin deacetylase to cyanogen bromide- activated Sepharose 4B was 90% efficient, producing chitin deacetylase-linked Sepharose 4B at 1.4 mg of chitin deacetylase/ml of gel. By the method presented here, about 2.0 - 6.5 mg of pure specific IgG were isolated from every 10 ml of antiserum with the elution of pH 2.8 (2.0% to 5.0% of total protein after ammonium sulfate precipitation) . Total isolated specific IgG represents 4.5% to 8.0% of total protein after ammonium sulfate precipitation. The binding capacity of the chitin deacetylase-linked Sepharose 4B for anti-chitin deacetylase antibody was determined at 1.4 mg IgG/ml of gel.
Example 3: Second Method for Purifying Chitin Deacetylase
Frozen mycelia (2 gr) , prepared as described in Example 1, was thawed, minced and homogenized in 10 ml of 0.05 M Tris-HCl buffer (pH 7.4) containing 0.5 mM PMSF, 0.1 mM NEM and 150 mM NaCl, using an improvised glass-bead miller (2 gr glass beads per gram of wet mycelia) . All steps were performed at 4°C. This produced a homogenate which was centrifuged at 10,000 rpm for 30 minutes at 4°C. The supernatant (12.2 ml; 4.6 mg/ml; 56.0 mg) is referred to as the crude extract. The extract was then incubated in a waterbath set at 50°C for 15 minutes and rapidly cooled in ice. Precipitated protein was removed by centrifugation at 35,000 rpm for 45 minutes at 4°C.
Five milligrams of the pure lower affinity rabbit IgG, described in Example 2, was dialyzed against the coupling buffer (pH 8.3) and mixed with 5 ml of swollen CNBr- activated Sepharose 4B to prepare an immunoadsorbent. The IgG was coupled by the method described for chitin deacetylase coupling. The coupling of IgG to activated Sepharose 4B was 85% efficient, producing IgG-linked Sepharose at 1 mg IgG/ml of gel. This immunoadsorbent was used for chitin deacetylase purification.
The supernatant described above (11.5 ml; 0.54 mg/ml; 6.2 mg) was loaded onto the immunoadsorbent (packed in a column of dimensions 2 x 1.6 cm; 5 ml) previously equilibrated in 25 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl (buffer A) . The column was washed with buffer A until no absorption of 280 nm was evident in the effluents (non-specifically bound proteins were eluted with 25 mM Tris-HCl pH 7.4, IM NaCl). Specifically bound chitin deacetylase was eluted using 0.2 M glycine-HCl buffer (pH 2.8) at a flow rate of 35 ml/h. Eluate was immediately adjusted to pH 7.0 with IM Tris-HCl pH 9.0, dialyzed against buffer A and concentrated by ultrafiltration (300 μl; 40 μg/ml; 12 μg; 180 mU) .
Purification of chitin deacetylase by immunoadsorption (table 4) produced a specific activity of 1500 m units/mg for the desorbed enzyme and a yield of about 30%. Assessment of chitin deacetylase purity by SDS-PAGE shows a single band. Purification of chitin deacetylase by conventional methods (table 1) produced a pure enzyme with a specific activity of 3.23 units/mg and a yield of 11.8%. The maximum binding capacity of the immunoadsorbent was determined at 42 μg of chitin deacetylase/ml of gel (4% of the antigen binding sites remain available for binding antigen after covalent immobilization to the matrix) .
TABLE 4
Purification of Chitin Deacetylase
By Immunoadsorption
Total Enzyme Protein activity
Step (mg) (munits)
Crude extract 56.0 50 C treatment 6.2 Immunoadsorbent 0.012
Equivalents
Those skilled in the art will know, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other equivalents are intended to be encompassed by the following claims.

Claims

1. An essentially pure chitin deacetylase preparation.
2 An essentially pure chitin deacetylase preparation of Claim 1 wherein the chitin deacetylase has a molecular weight of about 75-80 kilodaltons.
3. An essentially pure chitin deacetylase preparation of Claim 2 wherein the chitin deacetylase has a pi of about 3.0.
4. An essentially pure preparation of chitin deacetylase prepared by: a) providing a mycelial extract from a fungal culture; b) adding ammonium sulfate to the extract to a concentration of about 2.1 M; c) removing non-soluble material from the liquid phase; d) passing the liquid phase from step c) over a hydrophobic column; e) eluting the bound material from the hydrophobic column; f) adjusting the pH of the eluted material from step e) to produce a solution having a pH of about 8; g) passing the solution from step f) over a strong anion exchange column; h) collecting fractions from the strong anion exchange column and pooling fractions with chitin deacetylase activity; i) adjust the pH of the pooled fractions from step h) to about 3.5; j) passing the solution from step i) over a strong cation exchange column and collecting the flow through.
5. A method for isolating essentially pure chitin deacetylase comprising: a) providing a cellular extract from an organism which produces chitin deacetylase; b) adding ammonium sulfate to the cellular extract to a concentration of about 2.1 M; c) removing non-soluble material from the liquid phase; d) passing the liquid phase from step c) over a hydrophobic column; e) eluting the bound material from the hydrophobic column; f) adjusting the pH of the eluted material from step e) to produce a solution having a pH of about 8; g) passing the solution from step f) over a strong anion exchange column; h) collecting fractions from the strong anion exchange column and pooling fractions with chitin deacetylase activity; i) adjusting the pH of the pooled fractions from step h) to about 3.5; j) passing the solution from step i) over a strong cation exchange column and collecting the flow through.
6. A method of Claim 5 wherein the organism is Mucor rouxii.
A method for isolating essentially pure chitin deacetylase from a fungus which produces the enzyme comprising the steps of: a) providing mycelia from a fungal culture; b) disrupting the mycelia in an extraction buffer; c) removing non-soluble material from the liquid phase; d) incubating the liquid phase from step c) at a temperature of about 50 degrees C for about 30 minutes; e) removing non-soluble material from the liquid phase; f) adding ammonium sulfate to the liquid phase from step e) to a concentration of about 2.1 M; g) removing non-soluble material from the liquid phase; h) passing the liquid phase from step g) over a hydrophobic column; i) eluting the bound material from the hydrophobic column; j) adjusting the pH of the eluted material from step j) to produce a solution having a pH of about 8; k) passing the solution from step j) over a strong anion exchange column; 1) collecting fractions from the strong anion exchange column and pooling fractions with chitin deacetylase activity; m) adjust the pH of the pooled fractions from step 1) to about 3.5; n) passing the solution from step m) over a strong cation exchange column and collecting the flow through.
8. A method of Claim 7 wherein the fungus is Mucor rouxii.
9. Antiserum specifically reactive with chitin deacetylase.
10. Purified immunoglobulin specifically reactive with chitin deacetylase.
11. The purified immunoglobulin of Claim 10 wherein the immunoglobulin is of the isotype IgG.
12. A method for purifying chitin deacetylase comprising: a) providing an immunoadsorbent comprising immunoglobulin specifically reactive with chitin deacetylase linked to a solid support; b) contacting a crude cellular extract from an organism which produces chitin deacetylase with the immunoadsorbent under conditions appropriate for the specific binding of chitin deacetylase to the immunoadsorbent; c) washing the immunoadsorbent to remove non- specifically bound material; and d) eluting the purified chitin deacetylase from the immunoadsorbent.
13. A method for purifying chitin deacetylase from a fungus which produces the enzyme, comprising the steps of: a) providing mycelia from a fungal culture; b) disrupting and solubilizing the mycelia; c) removing non-soluble material from the liquid phase; d) performing a temperature cycling step which results in the precipitation of undesired protein; e) removing the non-soluble protein from step d) ; f) contacting the aqueous phase from step e) with an immunoadsorbent comprising immunoglobulin, specifically reactive with chitin deacetylase, linked to a solid support, under conditions appropriate for the specific binding of chitin deacetylase to the immunoadsorbent g) washing the immunoadsorbent to remove non- specifically bound material; and h) eluting the purified chitin deacetylase from the immunoadsorbent.
14. A method of Claim 13 wherein the fungus is Mucor rouxii.
15. A method for producing chitosan comprising contacting chitin with an essentially pure chitin deacetylase preparation under conditions appropriate for the enzymatic deacetylation of chitin.
16. Chitosan produced by contacting chitin with an essentially pure chitin deacetylase preparation under conditions appropriate for the enzymatic deacetylation of chitin.
EP92922352A 1991-10-09 1992-10-07 Purified chitin deacetylase Expired - Lifetime EP0610320B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US773724 1991-10-09
US07/773,724 US5219749A (en) 1991-10-09 1991-10-09 Process for isolating and preparing purified chitin deacetylase
PCT/US1992/008529 WO1993007262A2 (en) 1991-10-09 1992-10-07 Purified chitin deacetylase

Publications (2)

Publication Number Publication Date
EP0610320A1 true EP0610320A1 (en) 1994-08-17
EP0610320B1 EP0610320B1 (en) 2004-01-21

Family

ID=25099129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92922352A Expired - Lifetime EP0610320B1 (en) 1991-10-09 1992-10-07 Purified chitin deacetylase

Country Status (9)

Country Link
US (1) US5219749A (en)
EP (1) EP0610320B1 (en)
JP (1) JPH07501937A (en)
KR (1) KR100286078B1 (en)
AT (1) ATE258225T1 (en)
AU (1) AU669676B2 (en)
CA (1) CA2120328A1 (en)
DE (1) DE69233287D1 (en)
WO (1) WO1993007262A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109609485A (en) * 2019-01-02 2019-04-12 吉林中粮生化有限公司 A kind of chitin deacetylase and its application

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004795A (en) * 1991-10-09 1999-12-21 Institute For Molecular Biology And Biotechnology DNA encoding chitin deacetylase preparations
US5525502A (en) * 1991-10-09 1996-06-11 Institute For Molecular Biology & Biotechnology/Forth DNA encoding chitin deacetylase
CA2158056A1 (en) * 1993-03-29 1994-10-13 William H. Velander Method of coupling ligands within porous supports (p.e. azlactone) and uses thereof
SE509662C2 (en) * 1993-04-29 1999-02-22 Tetra Laval Holdings & Finance Packaging laminate coated with a water-insoluble chitosan compound and methods of making the packaging laminate
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5686115A (en) * 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5635493A (en) * 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US5624679A (en) * 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5846952A (en) * 1993-12-01 1998-12-08 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery
AU2662995A (en) * 1994-06-02 1996-01-04 Vitaphore Corporation Lysozyme-degradable biomaterials
US5762903A (en) * 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
JP2615443B2 (en) * 1995-03-13 1997-05-28 工業技術院長 Method for producing N-acetyl-D-glucosamine deacetylase
JP3062591B2 (en) * 1997-05-30 2000-07-10 農林水産省食品総合研究所長 p-Nitrophenyl 2-acetylamino-4-O- (2-amino-2-deoxy-β-D-glucopyranosyl) -2-deoxy-β-D-glucopyranoside and salts thereof and a method for producing the same
JP3030431B2 (en) * 1997-12-02 2000-04-10 農林水産省食品総合研究所長 Chitin deacetylase gene, vector containing the gene, and transformant
CA2313836C (en) * 2000-03-15 2009-06-09 Cargill, Incorporated Chitosan and method of preparing chitosan
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US7816514B2 (en) * 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US6693188B2 (en) 2001-08-08 2004-02-17 Cargill Incorporated N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine
US20020115639A1 (en) * 2001-02-16 2002-08-22 Weiyu Fan Glucosamine and method of making glucosamine from microbial blomass
US8222232B2 (en) * 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7923437B2 (en) * 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
BE1014638A6 (en) 2002-02-12 2004-02-03 Univ Liege Method of preparation of derivatives of cell wall from biomass.
BR0303666A (en) * 2002-04-02 2004-07-27 Cargill Inc Chitosan Production
US20060003965A1 (en) * 2002-11-01 2006-01-05 Fosdick Lawrence D N-acetyl-d-glucosamine (nag) supplemented food products and beverages
US20060058263A1 (en) * 2002-11-01 2006-03-16 Rogers Brent D Heat pasturized liquids containing glucosamine
AU2003290567B2 (en) * 2002-11-01 2008-12-04 Cargill, Incorporated Heat pasteurized liquids containing glucosamine
US20040229341A1 (en) * 2003-02-12 2004-11-18 Marie-France Versali Method for the production of chitin deacetylase
ES2621018T3 (en) * 2007-02-19 2017-06-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
CN101735337B (en) * 2009-12-31 2012-05-30 中国科学院微生物研究所 Method for preparing chitin and chitosan
MX342912B (en) 2010-04-15 2016-10-19 Marine Polymer Tech Inc Anti-bacterial applications of poly -n-acetylglucosamine nanofibers.
US20140127310A1 (en) 2011-04-15 2014-05-08 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
WO2014140167A1 (en) 2013-03-14 2014-09-18 Dsm Ip Assets B.V. Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
CN103980344A (en) * 2014-04-09 2014-08-13 中国药科大学 Method for separating and purifying fusion protein containing chitin binding domain
CN104262507B (en) * 2014-10-31 2016-05-18 江苏财经职业技术学院 A kind of ultrasonic synergistic CDA enzyme is prepared the method for lobster shell shitosan
CN107384883B (en) * 2017-08-24 2021-03-16 河北民族师范学院 Method for preparing carotenoid lyase
CN113373134B (en) * 2021-07-30 2024-02-20 江苏海飞生物科技有限公司 Extraction method of N-acetylglucosamine deacetylase
CN117384894B (en) * 2023-12-04 2024-02-09 中国水产科学研究院黄海水产研究所 Deacetylase and encoding gene, recombinant plasmid, recombinant bacterium and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1104351B (en) * 1978-06-14 1985-10-21 Muzzarelli Riccardo THE GLUCAN COMPLEX CHITOSANO THE METHOD OF ITS PRODUCTION FROM MUSHROOMS AND YEASTS AND ITS USES
US4958011A (en) * 1983-06-27 1990-09-18 Bade Maria L Ester-stabilized chitin
US4806474A (en) * 1985-06-10 1989-02-21 Miles Inc. Preparation of mycelial chitosan and glucan fractions from microbial biomass

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9307262A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109609485A (en) * 2019-01-02 2019-04-12 吉林中粮生化有限公司 A kind of chitin deacetylase and its application

Also Published As

Publication number Publication date
DE69233287D1 (en) 2004-02-26
JPH07501937A (en) 1995-03-02
KR100286078B1 (en) 2001-05-02
AU2796892A (en) 1993-05-03
WO1993007262A2 (en) 1993-04-15
WO1993007262A3 (en) 1993-07-22
US5219749A (en) 1993-06-15
EP0610320B1 (en) 2004-01-21
ATE258225T1 (en) 2004-02-15
AU669676B2 (en) 1996-06-20
CA2120328A1 (en) 1993-04-15

Similar Documents

Publication Publication Date Title
US5219749A (en) Process for isolating and preparing purified chitin deacetylase
AU648655B2 (en) Adsorbed cellular fibronectin and process for separating and purifying fibronectins
Devi et al. Fractionation, purification, and preliminary characterization of polygalacturonases produced by Aspergillus carbonarius
WO1994029348A2 (en) Production of antibody fragments
US5525502A (en) DNA encoding chitin deacetylase
FI88308C (en) FOERFARANDE FOER RENGOERING AV TPA FRAON RAOAPREPARAT
Kadner et al. A Repressible Alkaline Phosphatase in Neurospora crassa: II. Isolation and Chemical Properties
CA1239094A (en) PRODUCTION OF MONOMERIC HUMAN .gamma.-INTERFERON
Anttinen et al. Affinity chromatography of collagen glucosyltransferase on a UDP-glucose derivative coupled to agarose
Kohno et al. Purification and properties of 4-L-aspartylglycosylamine amidohydrolase from hog kidney
US6297040B1 (en) Chitin deacetylase preparations
US5075230A (en) Stabilized plasminogen activator precursor and method of producing the same
EP0298991B1 (en) Novel lectins derived from bacterial pili
US4087328A (en) Purification and immobilization of sulfhydryl oxidase
EP0367302A2 (en) Process for semi-synthesis of human insulin, water-soluble cross-linked Achromobacter protease I for use therein and a process for preparing the same
Freeman et al. Isonitrile derivatives of polysaccharides as supports for the covalent fixation of proteins and other ligands
Einarsson et al. Coupling of proteins and other amines to Sepharose by bromine oxidation and reductive amination
CA2002446A1 (en) Method for the isolation of purification of cu/zn superoxide dismutase
JPH0244510B2 (en)
JP2739232B2 (en) Method of using cellulose gel having biological affinity
JP2714817B2 (en) Method for producing urokinase precursor
JPS6222600B2 (en)
JPS63258899A (en) Lectin originated from human placenta
GB1592535A (en) Proteinase from trypanosoma its preparation use and antibodies thereto
JPH0121956B2 (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980624

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12P 19/26 B

Ipc: 7C 07K 14/37 B

Ipc: 7C 12N 9/80 A

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040121

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040121

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20040121

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040121

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040121

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040121

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040121

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040121

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69233287

Country of ref document: DE

Date of ref document: 20040226

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040421

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040421

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040422

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041007

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041007

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041031

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20041022

EN Fr: translation not filed
EN Fr: translation not filed
REG Reference to a national code

Ref country code: FR

Ref legal event code: ERR

Free format text: BOPI DE PUBLICATION N: 05/03 PAGES: 237 PARTIE DU BULLETIN CONCERNEE: BREVETS EUROPEENS DONT LA TRADUCTION N'A PAS ETE REMISE A I'INPI IL Y A LIEU DE SUPPRIMER: LA MENTION DE LA NON REMISE.

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20041007

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A